miRagen Therapeutics Inc Receives a New Rating from a Top Analyst

By Austin Angelo

Cowen & Co. analyst Ritu Baral assigned a Buy rating to miRagen Therapeutics Inc (NASDAQ: MGEN) yesterday. The company’s shares opened today at $7.15.

Baral wrote:

“MGEN reported 3Q and provided an overview of recent progress and upcoming.”

According to TipRanks.com, Baral is a top 100 analyst with an average return of 24.2% and a 52.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Global Blood Therapeutics.

miRagen Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $24.

The company has a one-year high of $18 and a one-year low of $4.44. Currently, miRagen Therapeutics Inc has an average volume of 90.34K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Signal Genetics, Inc. is a commercial stage, molecular diagnostic company. It provides innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. The company was founded in January 2010 and is headquartered in Carlsbad, CA.